Skip to main content
OpenTrials
Completed

NCT Number: NCT05489484

Performance and Safety Evaluation of MD-Shoulder Collagen Medical Device in the Treatment of Rotator Cuff Syndrome

Rotator Cuff Syndrome is a commonly encountered musculoskeletal disorder in clinical practice, with an incidence ranging from 0.3% to 5.5%, and an annual prevalence of 0.5% to 7.4%. In addition, over time, with a monthly rate of 0.26%, this condition can progress to complete rotator cuff tendon injury resulting in worsening pain and shoulder function. The etiology of Rotator Cuff Syndrome is still controversial. What the investigators know is that in tendinopathies there are histological changes in the structure of the tendons, resulting in a change in the mechanical properties of the tendons and leading to a chronic often disabling pain condition. Although conservative therapy should still be considered the first choice in cuff tendinopathies, The clinical results of the various types of nonsurgical treatments are still mixed and often show poor efficacy. This explains the growing interest of the scientific community in developing new biological therapies that can both improve shoulder function and promote tendon healing. The aim of the study is to evaluate, through the Constant Murley Score (CMS), the performance of intra-articular treatment with a collagen-based medical device (MD-Shoulder Collagen Medical Device) in recovering joint function and reducing pain in Rotator Cuff Syndrome.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rotator Cuff Tendinitis Muscular Diseases Musculoskeletal Diseases Osteogenesis Imperfecta, Type IV Rotator Cuff Injuries Rupture Shoulder Injuries Syndrome Rotator Cuff Tendinopathy Tendinoses, Rotator Cuff Tendon Injuries Wounds and Injuries

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Gaetano Pini CTO

Milan, MI, 20122, Italy

About this study

This is a pilot monocentric Clinical Investigation based on a one sample design. The purpose of this research is to evaluate, through the CMS functional scale, the performance of intra-articular treatment with a collagen-based medical device in recovering joint function and reducing associated pain. The safety of the treatment will also be assessed. Variables will be assessed at 6 different times points: at baseline (day0), after weeks 2, weeks 4, months 3, months 6, and after months 12.

The total duration of the study will be 16 months. There will be a 4-month subject selection and recruitment period and a 12-month treatment and observation period.

A total of 24 subjects with painful shoulder in Rotator Cuff Syndrome will be enrolled. The recruitment phase will be closed no sooner than the number of subjects planned in the study has been reached. Enrollment will involve subjects with rotator cuff syndrome who are eligible according to the selection criteria. Diagnosis will be performed by the Principal Investigator through clinical examination and instrumental investigation with shoulder MRI. The investigators will explain the rationale for the investigation plan and the procedures involved to the eligible subjects. Consent to participate in the study will then be sought. Prior or ongoing the treatments of any kind will be documented.

In order to monitor analgesic consumption (Celecoxib 200mg / Paracetamol 1000 mg) used during the study in case of pain onset, a clinical diary will be given to the subject in which to indicate the day and dose of medication used.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects with age > 18 years.
  • Subjects with shoulder pain for at least 3 month.
  • Subjects with a diagnosis of rotator cuff tendinopathy, subacromial conflict syndrome, partial rotator cuff tendon injuries (injuries A and B according to Snyder's Classification).
  • Subjects with a CMS score between 40 and 75.
  • Subjects who understood and signed the Informed Consent to Active Participation in the study.
  • Subjects able to understand the conditions of the study and participate throughout the duration.

Exclusion criteria

  • Subjects with complete rotator cuff lesions (C lesions according to Snyder's classification).
  • Subjects with shoulder instability.
  • Subjects with adhesive retractile capsulitis.
  • Subjects undergoing Hyaluronic Acid and/or cortisone infiltration in a period < 3 months.
  • Subjects with diabetes mellitus.
  • Subjects with uncontrolled thyroid disease.
  • Subjects with coagulopathies.
  • Subjects on chronic treatment with immunosuppressants.
  • Subjects with an allergy to porcine collagen.
  • Subjects in pregnancy or lactation.

Treatment and study plan

MD-Shoulder Collagen Medical Device

Device

Only one experimental group is scheduled by the Investigation Plan to be treated with 2-mL volume ultrasound-guided infiltrations of MD-Shoulder Collagen Medical Device (GUNA, Milan-Italy).

Subjects will be treated with number one ultrasound-guided infiltration at the time of enrollment, 2 weeks after enrollment, and 4 weeks after enrollment.

Intra-articular infiltrations will be performed with 5cc syringes and 22-gauge needles.

MD-Shoulder Collagen Medical Device will be infiltrated within the scapulohumeral joint under conditions of complete asepsis.

Primary outcomes

  1. Change From Baseline in Constant-Murley Score (CMS) at 3 Months

    Time frame: 3 months after baseline (Day 0)

    The primary outcome is the change from baseline in the Constant-Murley Score (CMS) at 3 months after the first intra-articular injection. The CMS is a validated clinical scale ranging from 0 to 100 points, where higher scores indicate better shoulder function and less pain. It includes four subdomains: pain (15 points), activities of daily living (20 points), range of motion (40 points), and strength (25 points). An increase of at least 13 points is considered very clinically significant. Results will be analyzed as the mean change in CMS from baseline (Day 0) to Month 3.

    Unit of Measure:

    Points on the Constant-Murley Scale (0-100)

Secondary outcomes

  1. Evaluation of MD-Shoulder Collagen Medical Device Performance Using the Constant-Murley Score

    Time frame: months 6, months12

    Secondary Endpoints will consist of the evaluation of MD-Shoulder Collagen Medical device through CMS at months 6 and months 12 compared to day 0.

  2. Evaluation of MD-Shoulder Collagen Medical Device With Numeric Rating Scale

    Time frame: weeks 2, weeks 4, months 3, months 6, months 12

    Secondary Endpoints will consist of the evaluation of MD-Shoulder Collagen Medical Device, with NRS (Numeric Rating Scale) at weeks 2, weeks 4, months 3, mouth 6, mouth 12 compared to day 0.

  3. Evaluation of MD-Shoulder Collagen Medical Device With American Shoulder and Elbow Surgeons (ASES)Scores Range From 0 to 100 With a Score of 0 Indicating a Worse Shoulder Condition and 100 Indicating a Better Shoulder Condition

    Time frame: months 3 months 6, months 12

    Secondary Endpoints will consist of the evaluation of MD-Shoulder Collagen Medical with American Shoulder and Elbow Surgeons (ASES), Simply Shoulder Test (SST) and Range Of Motion (ROM) at months 3, mouth 6, mouth 12 compared to day 0

  4. Evaluation of MD-Shoulder Collagen Medical Device With Simply Shoulder Test (SST), the Items on the Scale Measure the Ability of the Affected Shoulder to Perform Work Duties, Dressing, Bathing, Lifting, Carrying and Throwing.

    Time frame: months 3, months 6, months12

    Secondary Endpoints will consist of the evaluation of MD-Shoulder Collagen Medical Device with simply shoulder test (SST) at months 3, mouth 6, mouth 12 compared to day 0

    number of "yes"/number of completed items 100 = % of "yes" response. 0 = worst and 100 = best function

  5. Evaluation of MD-Shoulder Collagen Medical Device With Range of Motion (ROM).

    Time frame: months 3, months 6, months12

    Secondary Endpoints will consist of the evaluation of MD-Shoulder Collagen Medical with Range Of Motion (ROM) at months 3, mouth 6, mouth 12 compared to day 0

  6. Evaluation of MD-Shoulder Collagen Medical With Cuff Integrity at Mouth 12 Compared to Day 0 by Performing With Magnetic Resonance Imaging (MRI) of the Treated Shoulder.

    Time frame: month 12

    Secondary Endpoints will consist of the evaluation of MD-Shoulder Collagen Medical with cuff integrity at mouth 12 compared to day 0 by performing with Magnetic Resonance Imaging (MRI) of the treated shoulder.

  7. Evaluation of MD-Shoulder Collagen Medical With Assessment of Analgesic Drug Unit Consumption Based on Clinical Diary at Various Phases of the Study.

    Time frame: months 3, months 6, months 12

    Secondary Endpoints will consist of the evaluation of MD-Shoulder Collagen Medical with Analgesic consumption at various phases of the study with use of clinical diary

  8. Safety Evaluation

    Time frame: weeks 2, weeks 4, months 3, months 6, months 12

    Evaluation of Adverse Events.

Sponsors and collaborators

Lead sponsor

Guna S.p.a

Industry

Registry information

Official study title

Performance and Safety Evaluation of Type I Collagen (MD-Shoulder Collagen Medical Device) in the Treatment of Rotator Cuff Syndrome ''ROPIRAMED PILOT STUDY''

Acronym: ROPIRAMED

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Aug 5, 2022
Registry last updated
Jul 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.